Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons.

ABSTRACT:

Context

Diabetes in neonates nearly always has a monogenic etiology. Earlier sulfonylurea therapy can improve glycemic control and potential neurodevelopmental outcomes in children with KCNJ11 or ABCC8 mutations, the most common gene causes.

Objective

Assess the risks and benefits of initiating sulfonylurea therapy before genetic testing results become available.

Design, setting, and patients

Observational retrospective study of subjects with neonatal diabetes within the University of Chicago Monogenic Diabetes Registry.

Main outcome measures

Response to sulfonylurea (determined by whether insulin could be discontinued) and treatment side effects in those treated empirically.

Results

A total of 154 subjects were diagnosed with diabetes before 6 months of

SUBMITTER: Carmody D 

PROVIDER: S-EPMC4255121 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature